DNA vs DRTS

Ginkgo Bioworks Holdings, Inc. vs Alpha Tau Medical Ltd. — Valuation Comparison 2026

DNA

Biotechnology
Ginkgo Bioworks Holdings, Inc.
Quality
6.1
out of 10
Value Trap
12
SAFE
Price
$9.46
Last close
Models
10/13
Active
VS

DRTS

Biotechnology
Alpha Tau Medical Ltd.
Quality
2.3
out of 10
Value Trap
6
SAFE
Price
$10.13
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DNA Fair ValueDNA Upside DRTS Fair ValueDRTS Upside
Bayesian DCF Intrinsic $0.65 -93.1% $2.66 -73.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.29 -65.3% $0.44 -95.7%
PWERM Option-Based $12.98 +37.2% $10.17 -1.2%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DNA vs DRTS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DNA vs DRTS — Which Stock Is More Undervalued?

DNA scores higher with a 6.1/10 quality rating vs DRTS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ginkgo Bioworks Holdings, Inc. (DNA) and Alpha Tau Medical Ltd. (DRTS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DNA currently trades at $9.46 with a QOC of 6.1/10, while DRTS trades at $10.13 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).